AstraZeneca's $50bn investment aims to establish a new drug manufacturing facility in Virginia and expand research and development across various US states, highlighting a significant commitment to US operations in response to looming tariffs on foreign pharmaceuticals.
Sir Pascal Soriot has repeatedly highlighted the need for Europe to enhance its incentives for new medicines, warning that jobs could relocate to the US if these conditions remain unchanged.
AstraZeneca's $2.5 billion investment in Beijing aims to strengthen its research capabilities and move beyond recent controversies by fostering collaborations with local biotech companies.